On Friday, Nov. 13 at 1:00 p.m. ET, Genentech CEO Alexander Hardy will join Washington Post columnist David Ignatius for a one-on-one conversation about therapeutics and vaccines being created to combat COVID-19.

Genentech, the American biotechnology company, began trials in March to see if one of its existing medicines could be used against COVID-19 as it spread across the U.S. causing hospital overruns and thousands of deaths with a special effort to enroll diverse groups disproportionately impacted by the virus. While setting up these trials, the company changed ways of working to virtually meet the needs of patients who found themselves without access to their medicines and partnered with others to fight the pandemic.

This is the second installment of a special two-part series with the CEOs leading the global pursuit of a treatment and vaccine for COVID-19. From safety and science, to innovation and inclusion, to collaborating for the common good, we will hear the latest developments on current clinical trials and the challenges of chasing a pandemic.